Episode Details
William Curtis: Driving Diagnostic Excellence
Ep. 50
In Episode 50, we speak with CEO of nRichDX, William Curtis. nRichDX’s patented IVD-labeled platform is the result of an intensive technology development effort that commenced in 2016 and was commercially launched in November 2019. It’s a patented sample prep system that in its current state already provides up to 10x more genetic targets for liquid biopsy testing. It’s commercial stage with some highly regarded customers that cost-effectively improves test sensitivity, earlier detection and earlier intervention leading to superior outcomes. They have been supporting themselves with some angel money and contracts as they have developed both manual and semi-automated systems and data to support performance. The company is raising $20 mm to (1) develop a fully automated system using the exact same scalable technology and (2) to finally be able to invest in Sales and Marketing and commercialize their products.
Join us as we discuss the $5.53 billion liquid biopsy market, the evolution of early cancer detection, the rising importance for liquid biopsy abilities to find information about cancer diseases with the use of blood samples, William's MedTech entrepreneurial insights into launching companies tackling today's unmet clinical needs..
OTHER MEDTECH RADIO EPISODES
- All
- Entrepreneurship/Startups
- Leadership Spotlight
- Marketing & Product Development
- Professional Development
- Women in MedTech
- Young Professionals